Amylyx Pharmaceuticals (AMLX) Non Operating Income (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Non Operating Income of $2.5 million for Q1 2026, up 31.59% year-over-year from $1.9 million in Q1 2025, and down 31.68% quarter-over-quarter from $3.7 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Non Operating Income (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Non Operating Income history runs 6 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 31.59% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $9.2 million (down 15.67% YoY), while the FY2025 annual figure was $8.6 million, down 31.7% from the prior year.
- Non Operating Income for Q1 2026 stood at $2.5 million, down from $3.7 million in the prior quarter.
- The five-year high for Non Operating Income was $4.5 million in Q4 2023, with the low at $112000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $2.5 million (2026), against an average of $2.5 million.
- The sharpest annual moves came in 2022 and 2025: Non Operating Income jumped 8610.34% in 2022, then sank 60.57% in 2025.
- Amylyx Pharmaceuticals' Non Operating Income stood at $2.5 million in 2022, then jumped by 84.04% to $4.5 million in 2023, then slumped by 45.55% to $2.5 million in 2024, then surged by 47.67% to $3.7 million in 2025, then sank by 31.68% to $2.5 million in 2026.
- Business Quant data shows AMLX's Non Operating Income at $2.5 million in Q1 2026, $3.7 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | -13.20 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | - |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - | 2.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.27 Mn |
| Mar 31, 2026 | 2.50 Mn |
| Dec 31, 2025 | 3.65 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.90 Mn |
| Dec 31, 2024 | 2.47 Mn |
| Sep 30, 2024 | 2.96 Mn |
| Jun 30, 2024 | 3.59 Mn |
| Mar 31, 2024 | 3.58 Mn |
| Dec 31, 2023 | 4.54 Mn |
| Sep 30, 2023 | 3.69 Mn |
| Jun 30, 2023 | 3.81 Mn |
| Mar 31, 2023 | 3.46 Mn |
| Dec 31, 2022 | 2.47 Mn |
| Sep 30, 2022 | 800,000.00 |
| Jun 30, 2022 | 360,000.00 |
| Mar 31, 2022 | 112,000.00 |
| Dec 31, 2021 | -29,000.00 |
| Sep 30, 2021 | -224,000.00 |